We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

FUJIREBIO

Fujirebio is a global leader in the field of IVD testing with more than 50 years’ experience in the conception, devel... read more Featured Products: More products

Download Mobile App





Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy

By LabMedica International staff writers
Posted on 01 Nov 2022
Print article
Image: The ESPLINE SARS-CoV-2 is for in vitro diagnostic (IVD) use with immunochromatographic assay for the detection of SARS-CoV-2 antigen directly from nasopharyngeal swab fluid and is intended for use as an aid in the diagnosis of SARS-CoV-2 infection (Photo courtesy of Fujirebio)
Image: The ESPLINE SARS-CoV-2 is for in vitro diagnostic (IVD) use with immunochromatographic assay for the detection of SARS-CoV-2 antigen directly from nasopharyngeal swab fluid and is intended for use as an aid in the diagnosis of SARS-CoV-2 infection (Photo courtesy of Fujirebio)

Many health care providers are hopeful regarding COVID-19 testing programs that use accurate rapid antigen tests to reduce the burden on the health care system through early diagnosis of infection. Currently, various antigen-detecting rapid diagnostic tests (Ag-RDTs) for SARS-CoV-2 are commercially available.

The widespread use of testing outside medical institutions suggests that anterior nasal specimens, which can be safely self-collected by the patient, are now being used instead of nasopharyngeal specimens collected by medical staff. Therefore, to evaluate the usefulness of specimens collected from the anterior nasal cavity, understanding the viral load and diagnostic accuracy of tests performed using anterior nasal specimens is vital.

Pediatricians at the Jichi Medical University (Tochigi, Japan) and their colleagues conducted a prospective cross-sectional study from February 12, 2021 to September 30, 2021. They enrolled 16 patients (age range, <1 month-76 years) and samples were collected simultaneously from anterior nasal and nasopharyngeal sites continuously during hospitalization. The primary end points were the diagnostic accuracy of the Ag-RDT and utility of anterior nasal specimens.

The scientists determined the diagnostic performance of the RapidTesta SARS-CoV-2 test (Sekisui Medical Co., Ltd., Tokyo, Japan) and compare it with that of RT-PCR, using specimens collected from the anterior nasal and nasopharyngeal sites. Furthermore, ESPLINE SARS-CoV-2 (Fujirebio Co., Ltd., Tokyo, Japan), an Ag-RDT that has been marketed and widely used since May 2020, was used as a comparator representing the efficacy of common Ag-RDTs.

Four specimen swabs were taken simultaneously from each patient on admission: an anterior nasal and nasopharyngeal specimen from each nostril and also repeat samples. To judge the RapidTesta SARS-CoV-2 results objectively, the team evaluated the results using the RapidTesta Reader after visual assessment. RNA extraction was performed using the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany) with a 140-µL aliquot of each sample. A one-step RT-PCR (Thermo Fisher Scientific, Waltham, MA, USA) was performed which targets nucleotide 2 gene-specific primers for SARS-CoV-2.

The investigators reported that in total 226 sets of paired samples were obtained. In 88.2% of specimens, the viral load was high at the nasopharyngeal site. The mean cycle threshold values for the anterior nasal and nasopharyngeal sites were 32.4 and 29.9, respectively. Using the real-time polymerase chain reaction results as a reference, the Ag-RDT showed a 100% sensitivity up to day 6 of the illness, using specimens with moderate or high viral load (cycle threshold <30) from either site. From day 7, the sensitivity was 70.4% - 90.6% and 83.9% - 84.6% for the anterior nasal and nasopharyngeal sites, respectively. The specificity remained at 100%.

The authors concluded that they had demonstrated the diagnostic accuracy of the newly developed RapidTesta SARS-CoV-2 test for the accurate diagnosis of COVID-19 in terms of both sensitivity and specificity. The anterior nasal cavity was shown to be useful as a specimen collection site. The study was published on November 1, 2022 in the International Journal of Infectious Diseases.

Related Links:
Jichi Medical University
Sekisui Medical Co., Ltd
Fujirebio
Thermo Fisher Scientific

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Microbiology

view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more

Pathology

view channel
Image: The tool can improve precision oncology by accurately predicting molecular subtypes and therapy responses (Photo courtesy of Shutterstock)

Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.